TY - GEN
T1 - Supply chain risk assessment of generic medicine in Indonesia Using DEMATEL-Based ANP (DANP)
AU - Kharisma, S. A.
AU - Ardi, R.
N1 - Funding Information:
The authors would like to thank Directorate of Research and Community Engagements (DPRM) Universitas Indonesia for financially supporting this research under Hibah PITTA 2020 Number: NKB-1135/UN2.RST/HKP.05.00/2020.
Publisher Copyright:
© 2020 IEEE.
Copyright:
Copyright 2021 Elsevier B.V., All rights reserved.
PY - 2020/12/14
Y1 - 2020/12/14
N2 - In healthcare, pharmaceutical services are an inseparable part to support its sustainability by providing pharmaceutical products, including medicines. In Indonesia, the majority of prescribed medicines are generic medicines since the government of Indonesia published a regulation to prescribe generic medicines at the government's health facilities, including health facilities that cooperate with Jaminan Kesehatan Nasional (JKN), a national health insurance system. In result, the demand for generic medicines will increase as JKN participants increase. However, risks or uncertainties in the supply chain activities can hinder generic medicines supply. Therefore, this study aims to develop supply chain risk management of generic medicines in Indonesia with results to prioritize the risks. A Multiple-criteria decision-making (MCDM), DEMATEL (Decision Making Evaluation and Laboratory) based ANP (Analytical Network Process) (DANP) was used to assess the risks. The relations among risks also discussed in this study. The results show that the top five risks involve in generic medicines supply chain in Indonesia are shipping delay, failed to meet production capacity, the inefficiency of finance plan realization, production process failure, and increase price of raw material.
AB - In healthcare, pharmaceutical services are an inseparable part to support its sustainability by providing pharmaceutical products, including medicines. In Indonesia, the majority of prescribed medicines are generic medicines since the government of Indonesia published a regulation to prescribe generic medicines at the government's health facilities, including health facilities that cooperate with Jaminan Kesehatan Nasional (JKN), a national health insurance system. In result, the demand for generic medicines will increase as JKN participants increase. However, risks or uncertainties in the supply chain activities can hinder generic medicines supply. Therefore, this study aims to develop supply chain risk management of generic medicines in Indonesia with results to prioritize the risks. A Multiple-criteria decision-making (MCDM), DEMATEL (Decision Making Evaluation and Laboratory) based ANP (Analytical Network Process) (DANP) was used to assess the risks. The relations among risks also discussed in this study. The results show that the top five risks involve in generic medicines supply chain in Indonesia are shipping delay, failed to meet production capacity, the inefficiency of finance plan realization, production process failure, and increase price of raw material.
KW - DANP
KW - Generic medicines
KW - MCDM
KW - Risk management
KW - Supply chain management
KW - Supply chain risk
UR - http://www.scopus.com/inward/record.url?scp=85099762122&partnerID=8YFLogxK
U2 - 10.1109/IEEM45057.2020.9309793
DO - 10.1109/IEEM45057.2020.9309793
M3 - Conference contribution
AN - SCOPUS:85099762122
T3 - IEEE International Conference on Industrial Engineering and Engineering Management
SP - 716
EP - 720
BT - 2020 IEEE International Conference on Industrial Engineering and Engineering Management, IEEM 2020
PB - IEEE Computer Society
T2 - 2020 IEEE International Conference on Industrial Engineering and Engineering Management, IEEM 2020
Y2 - 14 December 2020 through 17 December 2020
ER -